Sales volume of the final dosage forms of Grindeks in the first quarter of 2015 was 19.2 million euros and has increased by 3.1 million euros or 19.1% in comparison to the first quarter of 2014. The sales amount in Russia, other CIS countries and Georgia reached 12.3 million euros in the first quarter of 2015, which is by 1.1 million euros or 8% less than in the first quarter of 2014. Thanks to successful business diversification and the development of company’s activities in new markets, turnover of the final dosage forms in the Baltic States and other European countries amounted to 7 million euros, which is by 4.1 million euros or 148% more than in the first quarter of 2014. The sales volume in Latvia in the first quarter of this year accounted to 1.5 million euros and has increased by 0.6 million euros or 70% comparing with the first quarter of last year.

In the first quarter of 2015, sales of the active pharmaceutical ingredients reached 3.1 million euros, which is by 0.5 million euros or 17.8% more than in the first quarter of 2014. Main markets of Grindeks active pharmaceutical ingredients are the EU countries, USA and Japan. The most required active pharmaceutical ingredients of Grindeks in the first quarter of 2015 were Oxytocin, 6-thioguanine, Pimobendan and Ursodeoxycholic acid.

The Chairman of the Board Mr. Juris Bundulis: “By using company’s accumulated knowledge and experience in 60 countries worldwide, Grindeks successfully supplements its product portfolio and activities in new markets. This year’s first quarterly results affirm that currently implemented business diversification and restructuring are bringing positive results. The further company’s development will depend on two relevant factors – fast entrance into new markets and recovery of the economic situation in the CIS countries”.

Grindeks unaudited financial statements 2015 Q1 (476 KB)